Impact of preemptive hospitalization on health outcomes at the temporary COVID-19 hospital in Mexico City: a prospective observational study.

Autor:	Vazquez RRV; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Gallardo-Rincón H; Mexico Carlos Slim Foundation, Lago Zurich 245, Presa Falcon Building (Floor 20), Miguel Hidalgo, Mexico City 11529, Mexico., Lomelín-Gascon J; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Ville Benavides R; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Juárez LM; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Bello HH; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Castañeda LM; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Chavarria AP; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Castillo PE; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Gonzalez LER; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Avendaño MA; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Berlanga ST; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Loza RAR; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Wyssmann RVÁ; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Lezama ES; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Romero AG; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Ortega MDN; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Acosta LV; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Schotman AC; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Montoya JB; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Rodriguez AG; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Ramos LMB; Temporary COVID-19 Hospital, Hipódromo de las Américas, Miguel Hidalgo, Mexico City, Mexico., Martinez-Juarez LA; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico., Saucedo-Martínez R; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico., Montoya A; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico., Tapia-Conyer R; Carlos Slim Foundation, Miguel Hidalgo, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in infectious disease [Ther Adv Infect Dis] 2021 Aug 27; Vol. 8, pp. 20499361211040325. Date of Electronic Publication: 2021 Aug 27 (Print Publication: 2021).
DOI:	10.1177/20499361211040325
Abstrakt:	Introduction: In response to the evolution of the coronavirus disease 2019 (COVID-19) pandemic, the admission protocol for the temporary COVID-19 hospital in Mexico City has been updated to hospitalize patients preemptively with an oxygen saturation (SpO 2 ) of >90%. Methods: This prospective, observational, single-center study compared the progression and outcomes of patients who were preemptively hospitalized versus those who were hospitalized based on an SpO 2 ⩽90%. We recorded patient demographics, clinical characteristics, COVID-19 symptoms, and oxygen requirement at admission. We calculated the risk of disease progression and the benefit of preemptive hospitalization, stratified by CALL Score: age, lymphocyte count, and lactate dehydrogenase (<8 and ⩾8) at admission. Results: Preemptive hospitalization significantly reduced the requirement for oxygen therapy (odds ratio 0.45, 95% confidence interval 0.31-0.66), admission to the intensive care unit (ICU) (0.37, 0.23-0.60), requirement for invasive mechanical ventilation (IMV) (0.40, 0.25-0.64), and mortality (0.22, 0.10-0.50). Stratification by CALL score at admission showed that the benefit of preemptive hospitalization remained significant for patients requiring oxygen therapy (0.51, 0.31-0.83), admission to the ICU (0.48, 0.27-0.86), and IMV (0.51, 0.28-0.92). Mortality risk remained significantly reduced (0.19, 0.07-0.48). Conclusion: Preemptive hospitalization reduced the rate of disease progression and may be beneficial for improving COVID-19 patient outcomes. Competing Interests: Conflict of interest statement: The Carlos Slim Foundation funded this study. The funding source was involved in the design of the study, analysis, interpretation of data, and in writing the manuscript. The authors HGR, JLG, RSM, LAMJ, and RTC are employees of the Carlos Slim Foundation in Mexico. RRVV, RVB, LMJ, MAA, STB, RVAW, ESL, MDNO, AGR, LMBR, PEC, LERG, ACS, JBM, AGR, APC, HHB, LVA, and RARL are employed full-time by the temporary COVID-19 hospital. The authors declare no other outside funding from any other organizations and declare no further conflicts. (© The Author(s), 2021.)
Databáze:	MEDLINE
Externí odkaz: